Tang Wei, Stearns Ralph A, Miller Randall R, Ngui Jason S, Mathvink Robert J, Weber Ann E, Kwei Gloria Y, Strauss John R, Keohane Carol A, Doss George A, Chiu Shuet-Hing L, Baillie Thomas A
Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
Drug Metab Dispos. 2002 Jul;30(7):778-87. doi: 10.1124/dmd.30.7.778.
(R)-N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]- 4-[4-(4-trifluoro-methylphenyl)thiazol-2-yl]benzenesulfonamide (1) is a potent and selective agonist of the human beta3-adrenergic receptor. We report herein the data from studies of the metabolism and excretion of 1 in rats. Five metabolites were identified in the bile of male Sprague-Dawley rats administered 3H-labeled 1 by either oral gavage (10 mg/kg) or intravenous injection (3 mg/kg). These included a pyridine N-oxide derivative (M2), a primary amine resulting from N-dealkylation and loss of the pyridinyl-2-hydroxyethyl group (M4), a carboxylic acid derived from N-dealkylation and loss of the pyridyl-2-hydroxyethyl amine (M5), and the corresponding taurine and isethionic acid conjugates (M1 and M3). Metabolites M1 and M3 also were identified in rats treated with M5 and were generated in incubations of M5 with rat liver subcellular fractions in the presence of ATP and coenzyme A with supplementary taurine or isethionic acid. These results suggest that M5 is the precursor of M1 and M3 and that the formation of these conjugated metabolites follows similar mechanisms of amino acid conjugation. On the other hand, M2, M4, and M5 were produced from 1 in an NADPH-dependent manner in incubations with liver microsomes from rats, dogs, monkeys, and humans. In human liver preparations, these routes of biotransformation were shown to be catalyzed by cytochrome P450 3A4. In a bidirectional transport assay, transport of 1 across a monolayer of cells expressing P-glycoprotein (Pgp) was observed to be similar to that of vinblastine, which is an established substrate of the transporter protein. This finding, together with the observation that the parent compound was excreted in the feces of bile duct-cannulated animals following intravenous dosing, suggests that 1 is subject to Pgp-mediated excretion from intestine of rats.
(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺(1)是一种强效且选择性的人β3-肾上腺素能受体激动剂。我们在此报告1在大鼠体内的代谢和排泄研究数据。在经口灌胃(10mg/kg)或静脉注射(3mg/kg)给予3H标记的1的雄性Sprague-Dawley大鼠胆汁中鉴定出了5种代谢物。这些代谢物包括吡啶N-氧化物衍生物(M2)、因N-脱烷基化和吡啶基-2-羟乙基基团丢失而产生的伯胺(M4)、因N-脱烷基化和吡啶基-2-羟乙胺丢失而衍生的羧酸(M5),以及相应的牛磺酸和羟乙基磺酸共轭物(M1和M3)。在用M5处理的大鼠中也鉴定出了代谢物M1和M3,并且在ATP和辅酶A存在以及补充牛磺酸或羟乙基磺酸的情况下,M5与大鼠肝脏亚细胞组分孵育时会生成M1和M3。这些结果表明M5是M1和M3的前体,并且这些共轭代谢物的形成遵循类似的氨基酸共轭机制。另一方面,在与大鼠、狗、猴子和人类的肝脏微粒体孵育时,M2、M4和M5以NADPH依赖的方式由1产生。在人肝脏制剂中,这些生物转化途径显示由细胞色素P450 3A4催化。在双向转运试验中,观察到1穿过表达P-糖蛋白(Pgp)的单层细胞的转运与长春碱相似,长春碱是该转运蛋白的一种已知底物。这一发现,连同静脉给药后母体化合物在胆管插管动物粪便中排泄的观察结果,表明1在大鼠肠道中会受到Pgp介导的排泄作用。